FMP
Altimmune, Inc.
ALT
NASDAQ
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
7.04 USD
-0.48 (-6.82%)
About
ceo
Dr. Vipin K. Garg Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://altimmune.com
exchange
NASDAQ
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryla...
CIK
0001326190
ISIN
US02155H2004
CUSIP
02155H200
Address
910 Clopper Road
Phone
240 654 1450
Country
US
Employee
59
IPO Date
May 26, 2017
Summary
CIK
0001326190
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
02155H200
ISIN
US02155H2004
Country
US
Price
7.04
Beta
0.06
Volume Avg.
5.01M
Market Cap
499.1M
Shares
-
52-Week
2.09-14.84
DCF
2.52
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.24
P/B
-
Website
https://altimmune.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ALT News
It looks like there's no news available.
